Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye

The combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-naïve and treatment-experienced patients. This study aims to present real-world data...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Umut Devrim Binay, Faruk Karakeçili, Bilgehan Aygen, Ayşin Kılınç Toker, İlhami Çelik, Neşe Demirtürk, Tuğçe Şimşek Bozok, Leyla Dursun, Fethiye Akgül, Güle Çınar, Özgür Günal, Ali Asan, Eyüp Arslan, Fatma Yılmaz Karadağ, Orçun Barkay, İrem Akdemir, Funda Şimşek, Emine Türkoğlu Yılmaz, Zeynep Ravza Eğilmez, Süda Tekin, The Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK)
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2025-06-01
Serie:	Viruses
Ämnen:	sofosbuvir/velpatasvir/voxilaprevir hepatitis C treatment real-world data
Länkar:	https://www.mdpi.com/1999-4915/17/7/931
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!